Anlotinib plus TQB2450 (PD-L1 blockade) combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer: A single-arm, open-label phase II clinical trial

被引：0
|
作者：
Jin, Shui-Ling
Qiao, Shishi
Li, Ren-Feng
Zhang, Weijie
He, Wei
Su, Chang
Li, Lu-Hao
Pan, Jie
Guo, Wen-Zhi
Zong, Hong
机构：
[1] Zhengzhou Univ, Affiliated Hosp 1, Dept Med Oncol, Zhengzhou, Peoples R China
[2] Zhengzhou Univ, Affiliated Hosp 1, Dept Hepatobiliary & Pancreat Surg, Zhengzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
D O I：
10.1200/JCO.2024.42.3_suppl.498
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：498 / 498
页数：1
相关论文
共 50 条
  • [21] Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
    Du, J.
    Tong, F.
    Sha, H.
    Sun, Y.
    Zhu, Y.
    Qi, L.
    Li, X.
    Li, W.
    Yang, Y.
    Li, Z.
    Xu, C.
    Ni, J.
    Zhang, X.
    Zhu, C.
    Wang, X.
    Qian, X.
    Liu, B.
    ANNALS OF ONCOLOGY, 2023, 34 : S1535 - S1535
  • [22] First-line TQB2450 plus anlotinib combined with paclitaxel and cisplatin for advanced esophageal squamous cell carcinoma (ESCC): Update results of a multi-center phase II trial.
    Wang, Junsheng
    Li, Ning
    Guo, Yanzhen
    Cheng, Yufeng
    Li, Baosheng
    Luo, Suxia
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] Paclitaxel and cisplatin combined with anlotinib as first line regimen for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicentre open-label phase II clinical trial
    Wang, J-S.
    Wu, T.
    Hong, Y-G.
    Guo, Y-Z.
    Luo, S-X.
    Li, N.
    Cheng, Y-F.
    Li, B-S.
    ANNALS OF ONCOLOGY, 2020, 31 : S910 - S911
  • [24] Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for patients with advanced ESCC: A multicenter, single-arm, open-label phase II clinical trial.
    Wang, Junsheng
    Wu, Tao
    Luo, Suxia
    Li, Ning
    Hong, Yonggui
    Guo, Yanzhen
    Cheng, Yufeng
    Li, Baosheng
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study
    Zhang, Qiyi
    Liu, Xingyu
    Wei, Shumei
    Zhang, Lufei
    Tian, Yang
    Gao, Zhenzhen
    Jin, Ming
    Yan, Sheng
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [26] TQB2450 injection combined with anlotinib hydrochloride capsule in the treatment of advanced, recurrent or metastatic endometrial cancer: A multicohort, open label, multicenter phase II clinical trial - The TQB2450-II-08 trial
    Wu, X.
    Liang, S.
    Chen, X.
    Hou, J.
    Wang, K.
    Wang, D.
    An, R.
    Zang, A.
    Li, X.
    Zhang, B.
    Qu, P.
    Duan, W.
    Yu, G.
    Wang, D.
    Yan, D.
    Wang, J.
    Yao, D.
    Wang, S.
    Zhao, W.
    Lou, H.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S802 - S802
  • [27] Benmelstobart (TQB2450) combined with anlotinib hydrochloride capsule in the treatment of advanced, recurrent, or metastatic endometrial cancer: A multicohort, open label, multicenter, phase II clinical trial (TQB2450-II-08)
    Wu, Xiaohua
    Chen, Xiaojun
    Wang, Ke
    Wang, Dong
    An, Ruifang
    Hou, Jianqing
    Yang, Ying
    Wang, Danbo
    Qu, Pengpeng
    Zhang, Bingzhong
    Duan, Wei
    Li, Xiumin
    Zang, Ai-Min
    Yu, Guohua
    Lou, Hanmei
    Yao, Desheng
    Wang, Shuzhen
    Yan, Dong
    Li, Liang
    Liu, Xiaowei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] Updated results of paclitaxel and cisplatin in combination with anlotinib as first-line treatment for patients with advanced ESCC: A multicenter, single-arm, open-label phase. clinical trial.
    Li, Ning
    Wu, Tao
    Hong, Yong-Gui
    Guo, Yanzhen
    Cheng, Yufeng
    Li, Baosheng
    Wang, Junsheng
    Luo, Suxia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 376 - 376
  • [29] Anlotinib plus Epirubicin Followed by Anlotinib Maintenance as First-line Treatment for Advanced Soft-tissue Sarcoma: An Open-label, Single-arm, Phase II Trial
    Wang, Zhi-ming
    Zhuang, Rong-yuan
    Guo, Xi
    Zhang, Chen-lu
    You, Yang
    Chen, Li-sha
    Liu, Wen-shuai
    Zhang, Yong
    Luo, Rong-kui
    Hou, Ying-yong
    Lu, Wei-qi
    Zhou, Yu-hong
    CLINICAL CANCER RESEARCH, 2022, 28 (24) : 5290 - 5296
  • [30] Benmelstobart (TQB2450) alone or combined with anlotinib in previously treated advanced endometrial cancer: updated results from a multicohort, open-label, multicenter phase II clinical trial TQB2450-II-08
    Wu, Xiaohua
    Chen, Xiaojun
    Luo, Xuezhen
    Wang, Ke
    Wang, Dong
    An, Ruifang
    Hou, Jianqing
    Yang, Ying
    Wang, Danbo
    Qu, Pengpeng
    Zhang, Bingzhong
    Duan, Wei
    Li, Xiumin
    Zang, Aimin
    Yu, Guohua
    Lou, Hanmei
    Yao, Desheng
    Wang, Shuzhen
    Yan, Dong
    Li, Liang
    Liu, Xiaowei
    Zhao, Weidong
    Chen, Zhengzheng
    Fei, Jing
    Li, Jundong
    Wang, Jing
    Wang, Zhilian
    Yao, Shuzhong
    Ning, Fangling
    Zhou, Huaijun
    Sun, Li
    Pan, Lingya
    Liu, Qing
    Yang, Haihua
    Wang, Li
    Zhang, Mingjun
    Chen, Xiaoxiang
    Yuan, Jianlin
    Zhang, Xinwen
    Zhang, Youzhong
    Liao, Qinping
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_3) : A6 - A6
12345